Intercept Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, utilizing our proprietary bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. Offices in New York, San Diego and London.
Company Growth (employees)
New York, US
Size (employees)
456 (est)+13%
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US

Key People at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Founder ,CEO & Board Member
Luciano Adorini

Luciano Adorini

Chief Scientific Officer

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has an office in New York
New York, US (HQ)
18 Desbrosses Street

Intercept Pharmaceuticals Data and Metrics

Intercept Pharmaceuticals Financial Metrics

Intercept Pharmaceuticals's revenue was reported to be $25 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

25 m

Net income (FY, 2016)

(412.8 m)

EBIT (FY, 2016)

(402.5 m)

Market capitalization (26-May-2017)

2.8 b

Closing share price (26-May-2017)


Cash (31-Dec-2016)

43.7 m
Intercept Pharmaceuticals's current market capitalization is $2.8 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


25 m

Operating expense total

427.5 m


(235.7 m)(453.3 m)(223.7 m)(402.5 m)

EBIT margin, %


Interest expense

14.2 m

Net Income

(186 m)(283.2 m)(226.4 m)(412.8 m)
Numbers are in $, USDY, 2002Y, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016


4.4 m15.4 m17.7 m45.5 m13.4 m20 m32.7 m43.7 m

Accounts Receivable

9.1 m


2.7 m6.1 m13.6 m9.4 m

Current Assets

147.6 m245.8 m641.7 m707.9 m

Total Assets

150.3 m254.1 m655.8 m739.3 m

Accounts Payable

Current Liabilities

8.9 m15.2 m47.4 m78.5 m

Additional Paid-in Capital

268.3 m700.4 m1.3 b1.4 b

Retained Earnings

(469.2 m)(695.6 m)(1.1 b)

Total Equity

82.4 m314.9 m

Financial Leverage

1.8 x2.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(67.8 m)(283.2 m)(226.4 m)(412.8 m)

Depreciation and Amortization

105.7 k442.8 k1.7 m3.8 m

Accounts Receivable

(9.1 m)


(1.7 m)4.3 m

Accounts Payable

7.3 m

Cash From Operating Activities

(28 m)(87.7 m)(162.9 m)(342.4 m)

Cash From Investing Activities

(70.2 m)(96.6 m)(389.5 m)(60.1 m)

Cash From Financing Activities

66.1 m191 m565.5 m414.4 m

Interest Paid

4.2 k
Y, 2016

Financial Leverage

2.3 x

Intercept Pharmaceuticals Market Value History

Intercept Pharmaceuticals Online and Social Media Presence

Intercept Pharmaceuticals News and Updates

Intercept Pharmaceuticals Company Life and Culture

You may also be interested in